Evaluation of the teratogenic potential in Ciba-Geigy Go 10213, a new nitroimidazole derivative: 1-methane-sulphonyl-3-(1-methyl-5-nitro-1H-imidazole-2-yl)-2- imidazolidinone, an amoebicide, trichomonicide and giardicide, in giardicide, in rats.
With a view to evaluate the possible teratogenic potential of 1-methane-sulphonyl-3-(1-methyl-5-nitro-1H-imidazole-2-yl)-2-imidazolidi none (Go 10213), groups of pregnant rats were medicated orally with: 0, 100, 300 and 600 mg/kg of the compound daily from day 6 to day 15 of gestation. Foetuses were removed on day 20 of gestation, and were examined for their mortality, size, weight and any gross malformation. One third of the foetuses were fixed in Bouin's Fluid and sectioned by Wilson's technique for histological evaluation. The remaining pups were examined for the skeletal anomalies. CIBA-GEIGY Go 10213 appears to be neither embryotoxic nor teratogenic to the rat-foetuses, when the mothers were medicated at the aforesaid doses, during their critical phase of the pregnancy.
D000014:Abnormalities, Drug-Induced / Q000209:etiology*; D000563:Amebicides / Q000633:toxicity*; D000818:Animals; D000981:Antiprotozoal Agents / Q000633:toxicity*; D000994:Antitrichomonal Agents / Q000633:toxicity*; D001842:Bone and Bones / Q000002:abnormalities; D005260:Female; D005872:Giardia / Q000187:drug effects*; D009593:Nitroimidazoles / Q000633:toxicity*; D011247:Pregnancy; D051381:Rats; D011919:Rats, Inbred Strains
D000563:Amebicides; D000981:Antiprotozoal Agents; D000994:Antitrichomonal Agents; D009593:Nitroimidazoles; C034473:satranidazole